Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141523

Published: 2020

Journal Articles

High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure

Kamil Wisniewski, Krzysztof Madry, Sebastian Grosicki, MD PhD, Piotr Małecki, Bartosz Pula, Marzena Watek, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 1360.

https://doi.org/10.1182/blood-2019-123843

Published: 2019

Journal Articles

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Marcin M Machnicki, MSc, Monika Pepek, MSc, Iwona Solarska, PhD, Joanna Niesiobedzka-Krezel, MD PhD, Ilona Seferynska, MD PhD, Joanna Gora Tybor, MD PhD, Magdalena Zawada, PhD, Tomasz Sacha, MD PhD, Waldemar Sawicki, MD PhD, Ewa Wasilewska, MD PhD, Katarzyna Pruszczyk, MD, Malgorzata Rydzanicz, PhD, Rafal Ploski, MD PhD, Tomasz Skorski, MD PhD, Tomasz Stoklosa, MD PhD

Blood (2019) 134 (Supplement_1): 4148.

https://doi.org/10.1182/blood-2019-129834

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Aleksandra Golos, MD PhD, Krzysztof Mądry, MD PhD, Karol Lis, Marta Sobas, MD, Agnieszka Ożańska, Magdalena Czemerska, Dorota Hawrylecka, Agnieszka Stelmach-Gołdyś, Karolina Chromik, Bartosz Pula, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 5422.

https://doi.org/10.1182/blood-2019-125711

Published: 2019

Journal Articles

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Blood (2019) 134 (Supplement_1): 4180.

https://doi.org/10.1182/blood-2019-125864

Published: 2019

Journal Articles

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Blood (2018) 132 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2018-99-112374

Published: 2018

Journal Articles

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka-Krezel, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Ewa Wasilewska, Tomasz Stoklosa, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2017) 130 (Supplement 1): 2887.

https://doi.org/10.1182/blood.V130.Suppl_1.2887.2887

Published: 2017

Journal Articles

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Elżbieta Patkowska, Andrzej Szczepaniak, Marta Baranska, Maciej Kazmierczak, Monika Paluszewska, Wieslaw Jedrzejczak, Renata Guzicka Kazmierczak, Wanda Knopinska Posluszny, Olga Grzybowska-Izydorczyk, Agnieszka Pluta, Jaroslaw Piszcz, Izabela Deren-Wagemann, Ewa Lech Maranda, Krzysztof Warzocha, Joanna Gora Tybor

Blood (2017) 130 (Supplement 1): 1311.

https://doi.org/10.1182/blood.V130.Suppl_1.1311.1311

Published: 2017

Journal Articles

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora-Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2016) 128 (22): 1909.

https://doi.org/10.1182/blood.V128.22.1909.1909

Published: 2016

Journal Articles

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Tomasz Sacha, Joanna Gora-Tybor, Monika Szarejko, MD PhD, Grażyna Bober, MD, Olga Grzybowska-Izydorczyk, Joanna Niesiobędzka-Krężel, MD, Marek Dudziński, MD, Ewa Wasilewska, MD PhD, Krzysztof Myśliwiec, MD, Justyna Gil, MD PhD, Michał Gniot, MD PhD, Iwona Pietkun, MD, Ewa Mędraś, MD PhD, Joanna Wącław, MD, Krzysztof Giannopoulos

Blood (2016) 128 (22): 629.

https://doi.org/10.1182/blood.V128.22.629.629

Published: 2016

Journal Articles

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Elzbieta Patkowska, MD, Joanna Gora Tybor, MDPhD, Ewa Lech Maranda, MDPhD, Maciej Kazmierczak, MDPhD, Marta Baranska, MD PhD, Andrzej Szczepaniak, MD, Monika Paluszewska, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Renata Guzicka Kazmierczak, MD PhD, Wanda Knopinska Posluszny, MD PhD, Olga Grzybowska Izydorczyk, MD PhD, Jaroslaw Piszcz, MD PhD, Izabela Deren Wagemann, MD PhD, Krzysztof Warzocha, MD PhD

Blood (2015) 126 (23): 1321.

https://doi.org/10.1182/blood.V126.23.1321.1321

Published: 2015

Journal Articles

Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML)

Anna Stepien, MSc, Alessandro Martino, PhD, Federico Canzian, PhD, Daniele Campa, PhD, Angelika Stein, Joanna Gora-Tybor, MD PhD, Tomasz Sacha, MD PhD, Dorota Link-Lenczowska, PhD, Izabela Florek, PhD, Witold Prejzner, MD PhD, Zofia Specht-Szwoch, Malgorzata Calbecka, MD PhD, Marcin Rymko, MD PhD, Marek Dudzinski, MD PhD, Pawel Gaj, PhD, Tadeusz Robak, MD, Krzysztof Warzocha, MD PhD, Krzysztof Jamroziak, MD PhD

Blood (2014) 124 (21): 5222.

https://doi.org/10.1182/blood.V124.21.5222.5222

Published: 2014

Journal Articles

Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib

Joanna Gora-Tybor, MD, PhD, Ewa Medras, MD, PhD, Malgorzata Calbecka, MD, PhD, Agnieszka Kolkowska, MD, Edyta Ponikowska-Szyba, MD, Tadeusz Robak, MD, PhD, Krzysztof Jamroziak, MD, PhD

Blood (2013) 122 (21): 1491.

https://doi.org/10.1182/blood.V122.21.1491.1491

Published: 2013

Journal Articles

Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?

Ida Franiak-Pietryga, PhD, Ewelina Ziolkowska, MSc, Barbara Ziemba, PhD, Dietmar Appelhans, PhD, Brigitte Voit, Prof., Joanna Gora-Tybor, Prof., Tadeusz Robak, Prof., Barbara Klajnert, Prof., Maria Bryszewska, Prof.

Blood (2012) 120 (21): 4601.

https://doi.org/10.1182/blood.V120.21.4601.4601

Published: 2012

Journal Articles

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

Blood (2011) 118 (21): 3915.

https://doi.org/10.1182/blood.V118.21.3915.3915

Published: 2011

Journal Articles

Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia

Joanna Gora-Tybor, Krzysztof Jamroziak, Zofia Szemraj, Janusz Szemraj, Ewa Lech-Maranda, Olga Grzybowska-Izydorczyk, Katarzyna Oszajca, Krzysztof Giannopoulos, Tadeusz Robak

Blood (2010) 116 (21): 4467.

https://doi.org/10.1182/blood.V116.21.4467.4467

Published: 2010

Journal Articles

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

Blood (2008) 112 (11): 2103.

https://doi.org/10.1182/blood.V112.11.2103.2103

Published: 2008

Journal Articles

Influence of Chromosomal Aberrations on Response to First Line Therapy in B-Cell Chronic Lymphocytic Leukemia: Interim Analysis of PALG-CLL3 Randomized Study Comparing Cladribine Plus Cyclophosphamide vs Fludarabine Plus Cyclophosphamide.

Tadeusz Robak, Jerzy Z. Blonski, Ewa Wawrzyniak, Aleksandra Palacz, Joanna Gora-Tybor, Krzysztof Jamroziak, Jaroslaw Piszcz, Janusz S. Kloczko, Dorota Koczkodaj, Malgorzata Kowal, Anna Dmoszynska, Andrzej Mital, Andrzej Hellmann

Blood (2007) 110 (11): 2046.

https://doi.org/10.1182/blood.V110.11.2046.2046

Published: 2007

NARROW

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report

High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML)

Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib

Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

Influence of Chromosomal Aberrations on Response to First Line Therapy in B-Cell Chronic Lymphocytic Leukemia: Interim Analysis of PALG-CLL3 Randomized Study Comparing Cladribine Plus Cyclophosphamide vs Fludarabine Plus Cyclophosphamide.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only